Search hospitals > New Hampshire > Manchester

Solinsky Center for Cancer Care

Claim this profile
Manchester, New Hampshire 03103
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Prostate Cancer
146 reported clinical trials
2 medical researchers
Photo of Solinsky Center for Cancer Care in ManchesterPhoto of Solinsky Center for Cancer Care in ManchesterPhoto of Solinsky Center for Cancer Care in Manchester

Summary

Solinsky Center for Cancer Care is a medical facility located in Manchester, New Hampshire. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Solinsky Center for Cancer Care is involved with conducting 146 clinical trials across 142 conditions. There are 2 research doctors associated with this hospital, such as Douglas Weckstein, MD and Ali Fleury, MD.

Area of expertise

1Cancer
Global Leader
Solinsky Center for Cancer Care has run 44 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Solinsky Center for Cancer Care has run 35 trials for Breast Cancer. Some of their research focus areas include:
ER positive
HER2 negative
Stage IV

Top PIs

Clinical Trials running at Solinsky Center for Cancer Care

Breast Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Anal Squamous Cell Carcinoma
Rectal Cancer
Bladder Cancer
Squamous Cell Carcinoma
Anal Cancer
Image of trial facility.

Hormone Therapy with or without Radiation

for Breast Cancer

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Solinsky Center for Cancer Care?
Solinsky Center for Cancer Care is a medical facility located in Manchester, New Hampshire. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Solinsky Center for Cancer Care is involved with conducting 146 clinical trials across 142 conditions. There are 2 research doctors associated with this hospital, such as Douglas Weckstein, MD and Ali Fleury, MD.